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Abstract Topotecan is a novel semisynthetic derivative of 
the anticancer agent camptothecin and inhibits the intra- 
nuclear enzyme topoisomerase I. The lactone structure of 
topotecan, which is in equilibrium with the inactive ring- 
opened hydroxy acid, is essential for this activity. The open 
form predominates at physiological pH. We performed a
pharmacokinetic study as part of a phase I study in patients 
with various types of solid tumors, where topotecan was 
administered in a 30-min infusion daily on 5 consecutive 
days every 3 weeks. The plasma kinetics of topotecan could 
be described best using an open two-compartment model 
with tV2(~) and tl/2([3) of 8.1 (range 0.3 to 40.7) min and 
132 (range 49 to 286) min, respectively. The plasma 
concentration-time profiles of the metabolite, however, 
could be described using a one-compartment model with 
tl/2(formation) of 29.0 (range 5.6-99.5) min and tl/2 
(elimination of 123.2 (range 32-265) rain, respectively. 
The lactone was the predominate form during the first hour 
from the start of infusion, but was rapidly converted into its 
ring-opened structure. The elimination rate of topotecan 
was independent ofthe dose. There were linear elationships 
between the dose (mg m -2 day-l), the area under the plasma 
concentration versus time curve (AUC) of topotecan and its 
metabolite, the total AUC, peak plasma lactone concentra- 
tions, and the time period that the topotecan concentrations 
remained above 10 nM. Different models were used to 
correlate pharmacokinetic and pharmacodynamic para- 
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meters. The percentage decrease in absolute neutrophil 
count (ANC) was related to these parameters and plots 
were well fitted by linear and sigmoidal Emax models. 
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Introduction 
Topotecan ([S]-9-dimethylaminomethyl- 10-hydroxy-camp- 
tothecin hydrochloride, SK&F 104864-A, NSC 609699), is 
a novel semisynthetic derivative of camptothecin, an anti- 
cancer drug derived from the Asian tree Camptotheca 
acuminata. Owing to camptothecin's serious and unpredict- 
able gastrointestinal, urothelial and myelosuppressive toxi- 
cities, clinical evaluation had to be discontinued in the early 
1970s [18, 19]. Compared with campthothecin, topotecan is
more water soluble, has reduced protein binding, and shows 
promising efficacy with a strongly reduced toxicity profile 
[2, 6, 11, 16, 22, 33]. The dose-limiting toxicity of topotecan 
is reversible myelotoxicity, especially granulocytopenia [22, 
23, 26, 30, 33], and mucositis [16]. 
Topotecan and other camptothecin a alogues inhibit the 
intranuclear enzyme topoisomerase I. Topoisomerase I is 
involved in RNA transcription, DNA replication, and 
possibly DNA repair and genetic rearrangements [1, 13, 
27]. During the process of winding and unwinding of DNA, 
torsional stresses and topological problems occur. Topo- 
isomerase nzymes change the conformation of a segment 
of DNA, resolving these mechanical obstacles [1]. Topote- 
can and other camptothecin analogues prohibit RNA tran- 
scription by stabilizing the DNA-topoisomerase I "cleavable 
complexes," which can result in lethal DNA damage during 
the courses of DNA replication [10, 13]. The lactone 
structure, which is in equilibrium with the open-ring 
hydroxy acid (SK&F 105992) at constant pH is essential 
for this function (Fig. 1) [11, 31]. The closed lactone ring 
predominates at acidic pH, but the reverse reaction of the 
parent into the metabolite predominates at physiological pH 
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Fig. 1 A, B Chemical structures of A topotecan and B its lactone ring- 
opened hydroxy acid. Both forms are in equilibrium at constant pH 
[2, 28]. The spontaneous hydrolysis of  the parent drug to the 
inactive form may, therefore, have important pharmacoki-  
netic and pharmacodynamic  implications. 
Al though neutropenia nd leukopenia were correlated to 
pharmacokinet ic  parameters, such as the AUC and peak 
plasma (Cm~x) concentrations of  topotecan in previous 
studies, only weak or absent relations were found [3 -5 ,  
32, 33]. 
We performed a pharmacokinet ic  study as part of a phase 
I study [30], using a h igh-performance l iquid chromatogra- 
phy [HPLC) procedure developed in our laboratory [2], by 
which we can measure selectively and simultaneously both 
topotecan and its lactone r ing-opened structure. The phar- 
macokinet ic data have been correlated with the pharmaco- 
dynamic outcome of the phase I study by using different 
mathematical  models. 
Patients and methods 
Patient population 
The patients, from whom phannacokinetic curves and clinical history 
were obtained, participated in a phase I trial of topotecan administered 
daily for 5 consecutive days every 3 weeks [30]. Eligibility criteria 
included ahistologically confirmed iagnosis of a solid malignant tumor 
no longer amenable to established forms of treatment. All patients had an 
acceptable bone marrow function (white blood cells (WBC) >4 x 109/1 
and platelets ->100 x 109/1), serum bilirubin -<26 btM and serum 
creatinine -<140 gM, with no prior history of hemorrhagic cystitis, 
WHO performance status -<2, life expectancy of --12 weeks and age 
18-75 years. All patients gave informed consent. 
Treatment plan 
Topotecan (SmithKline Beecham, King of Prussia, USA) was supplied as 
a clear yellow solution, containing the hydrochloride salt. This solution 
consisted of 2.57 mg of topotecan hydrochloride, quivalent to 2 mg of 
the free base, 52.1 mg of mgluconic aicd as its monopotassium salt, 
hydrochloric acid or sodium hydroxide for adjustment to pH 3.0, and 
water for injection USP q. s. to give 2.2 ml. The appropriate dosage of the 
drug was diluted in 48 mt of normal saline and administered i.v. by an 
infusion pump over 30 rain on 5 consecutive days every 3 weeks. Dose 
escalation was performed according to a modified Fibonacci scheme, 
using doses of 0.5, 0.65, 0.9, 1, 1.25, and 1.5 mg m 2 day 1, respectively. 
Intrapatient dose escalation was not permitted. To determine the 
hematological nd non-hematological toxicities, patients were evalu- 
ated weekly by clinical history, physical examination, serum chemistry 
and hematology screening. At the highest dose level hematology 
screening was performed twice a week. 
Pharmacokinetic studies 
Blood samples (5 ml each), taken from an indwelling i.v. cannula pIaced 
in the arm contralateral tothe arm receiving topotecan, were collected in 
heparinized tubes at 12 time points: before ach infusion, at 5, 10, 15 and 
30 rain during the infusion, and at 15 and 30 min and 1, 2, 3, 4, and 6 h 
after the end of the 30-rain infusion. Samples were collected uring the 
first and, if possible, during the 4th or 5th day of drug administration. 
Plasma was obtained by immediate centrifugation (5min; 1500 g) of the 
samples, followed by protein precipitation with cold methanol: 1 m] 
plasma was added to 4 mI of methanol (-30 ~ C). Thereafter, the 
substance was mixed and centrifuged (5 rain; 1500 g), and the 
clear supematant was transferred to a glass autosampler vial and stored 
(-30 ~ C) until analysis. Topotecan and its lactone ring-opened form were 
determined by a validated HPLC method using fluorescence detection, 
developed in our laboratory [2]. Using this method both forms are 
measured selectively and simultaneously in a single run. 
The plasma concentration [C(t)] versus time (t) curves of topotecan 
were analyzed using the pharmacokinetic software package MW/Pharm 
(MEDI~WARE, Groningen, The Netherlands) [21]. This non-linear 
least-squares, iterative regression program determines lopes and 
intercepts of the logarithmically plotted curves of multi-exponential 
functions. Initial estimates of the parameters were determined by an 
automated curve stripping procedure. In general, the mathematical 
equation describing plasma drug concentration C(t) at any time t 
during and after i.v. infusion is given during infusion by: 
N 
C(t) = E {Ci/(Ai x T~I) x (1 - e (-a' • t))} (Eq.1) 
i=l 
and post infusion by: 
N 
i=1 
where ~i is the exponent of the i-th exponential term, Ci is the initial 
concentration fthe i-th component of the cm-ve and ~nf is the infusion 
time. 
Topotecan kinetics could be best described by a bi-exponential 
model (N = 2), which gave the lowest Akaike information criterium. 
Curve fitting with this model yields the parameters C1, C2, )Vl and )v2. 
Respective half-lives were calculated from the equations tl/2(c0 = 0.693/ 
)va and tV2(13) = 0.693/s The area under the curve (AUC) was 
determined on the basis of the fitted curve as the exact integral of the 
C(t) versus t plots (of~C(t)dt) from t = 0 to infinity. Total plasma 
clearance (CL) was calculated by dividing the close by the AUC. The 
computer program also calculated the apparent first-order elimination 
rate constant from the central compartment (kl0), the intercompart- 
mental transfer ate constants km and k2l, the apparent distribution 
volume of the central compartment (Vc), and the apparent distribution 
volume during steady state (Vss) from C1, C2, t,1 and k2 with standard 
equations [7]. The pharmacokinetics of the topotecan metabolite were 
modelled by a bi-exponential equation describing both the formation 
and elimination of the metabolite in a one-compartment model: 
c~(t) - c (~ (-~ox~) - ~(~• (eq.3) 
where Cm(t) is the metabolite concentration at time t, )re and )vf are 
apparent first-order rate constants for metabolite limination and 
formation, respectively. C is a constant that depends on the values of 
),~, if, the apparent volume of distribution of the metabotite (Vm), the dose 
of topotecan and f~, the fraction of drug converted into the metabolite. 
Half-lives were calculated from the equations: tV2(1) = 0.693/)v~ and tV2 
(2) = 0.693/)vf. Other pharmacokinetic parameters were calculated with 
standard equations in the same manner as for topotecan [7]. 
The peak plasma concentrations (Cnm) of topotecan and its ring- 
opened form and the time to reach the maximal concentration (Tm~.) are 
observed experimental values. 
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Pharmacoldnetic-pharmacodynamic relationships 100 
The pharmacodynamics, e pecially the dose-limiting toxicities, were 90 
explored using plots of percentage decrease (%decr) in WBC and ANC 
versus the dose (mg m -2 day -1) and pharmacokinetic parameters. Since it ,~ 
has previously been suggested that the time period that the topotecan 
concentration is above 1 or 10 nM, among other parameters, can be 
important for toxicity [9], we investigated the following pharmacoki- 
netic parameters: the Cmax (nM), the time period that the topotecan 
concentration is above 1.0 nM or 10 nM topotecan (h), and the AUG ~ i ! ~ ~  
(gM.min) of topotecan, its metabolite, and the sum of both. 
The percentage decrease (%decr) is defined as: 
Pretreatment value - value of the nadir 
%decr Pretreatment value x 100% (Eq.4) 
The data were fitted using a (log-) linear model, a maximum effect (Emax) 
model and a sigmoidal maximum effect (sigEmax) model, as described by 
a modified Hill equation [15, 22]. 
The linear models were: 
%decr = a . (P) + b (Eq.5) 
log(%decr) = a . (P) + b (Eq.6) 
The Emax model was: 
%decr -  (MF,)(P) (Eq.7) 
(P,~0) + (P) 
The sigmoidal Em~ model was: 
%decr = (ME)(P)L4 
(ps0)• + (p)~ (Eq.8) 
Where a denotes the slope and b the intercept of the linear models, ME 
denotes the maximal effect, which is 100 (i. e. 100% decrease), P denotes 
the value of the pharmacokinetie parameter of interest, P50 the P that 
results in 50% of the ME, and H denotes the Hill constant, which 
describes the shape of the curve. In the Emax model the Hill constant is 
1. Linear regression analysis was performed to obtain a correlation 
coefficient (1-) and the slope and intercept of the linear model. The 
computer program NCSS (Number Cruncher Statistical System, Kays- 
ville, Utah, USA, 1992) and Quattro Pro (Borland International, Scotts 
Valley, Calif., USA, 1992) were used for all calculations. 
The performance of the model was evaluated by using the relative 
root mean square rror (%RMSE) value and its standard error (SE) [25]. 
The %RMSE is a measure of precision and is defined as: 
RMSE% N -1 - (pei) 2 9 100% 
i=1 
and the relative SE is defined as: 
SE% (N 9 (N -  1)) -1 9 ((pei) 2 - RMSE) 2 9 100% 
i=1 
where N is e. g. the number of P-pairs (i. e., true with predicted values), 
and pe is the prediction error [In(Ptrue value)--In(Ppredicted)]. The smaller: 
the %RMSE, the better the relation is described by the model. In the most 
predictive model the RMSE% approaches zero. 
Results 
Pharmacokinetics 
A total of 48 patients, with a variety of malignant solid 
tumors were entered in the original phase I study [30]. 
Median age was 56 years (range 25-75) ,  median perfor- 
5 
Time (hours) 
Fig. 2 Average plasma concentration-time curves of topotecan (R) 
and the lactone ring-opened metabolite ([2]) with their standard 
deviation at a dosage of 1.5 mg m-2 day 1 
mance status 1 (range 0 -2) ;  most patients were pretreated 
(75%). Complete plasma concentration time plots were 
obtained from 19 patients, and from 15 both on day 1 and 
on day 4 or 5. All patients were sampled during the first 
course. Figure 2 depicts the average plasma concentration- 
time curves for topotecan and its ring-opened form at a dose 
of 1.5 rag/m2; the shapes of curves at other dose were 
similar. 
The pharmacokinetics of topotecan could be described 
best with an open two-compartment model. The pharmaco- 
kinetic parameters obtained by means of this model are 
presented in Table 1. 
After cessation of the infusion, the topotecan curves 
exhibited a bi-exponential decay. The mean values and 
ranges (n = 34) for the linear segments were tt/2(c0: 
8.1 rain (range 0.3-40.7 min) and tl/2([3): 132 min (range 
49-286 rain). The mean values for the compartmental rate 
constants were: kin: 6.6 (range 0.75-66.6)  x 10 -2 rain -1, k12: 
19.5 (range 0.62-179.5) x 10 -2 rain-1 and k21:1.81 (range 
0.51-6.0)  x 10-2 rain q.  The mean _+ SD for the ratio k21] 
k12 was 0.32-t-0.24. The apparent distribution volumes of 
topotecan were Vc: 17.0 (range 0.8 to 57.7) 1/m 2, and 
apparent distribution volume at steady state, Vs~: 72.7 
(range 28.5-123.5) 1/m 2. The ratio )~2/k10 was 0.17___0.13. 
The mean total body clearance of topotecan was 0.57 (range 
0.25-0.99) 1 rnin-1 m-2. Concentrations above 10 nM were 
maintained for a median of 1.8 h (range 0 .8 -3 .2  h). The 
mean percentage of total drug excreted in the urine over the 
first 24 h on the 1st day of the 5-day course was 25.8% 
(range 7.0-58.6%).  Peak plasma concentrations of topote- 
can were reached at the end of the 30-min infusion and 
ranged between 24.8 and 169.8 nM. Most pharmacokinetic 
parameters failed to show dose-related trends (r <0.25),  
exceptions being Cma• (r = 0.44), the AUC of topotecan 
(r = 0.66), and the duration of concentrations over 10 nM 
(r = 0.78). 
In the first plasma samples the topotecan ring-opened 
form was already detectable. About 1 h after the start of the 
240 
Table 1 Pharmacokinetics of topotecan. (Pat. patient number with the 
day of the course in round brackets; Dose mg m -2 da~i; Cmax DJ~; AUC 
~tM 9 rain; tl/2(~), tl/2(~) min; klo, k~z k2~ 10 -2 rain-1.; V~, Vs~ l/m2; CL 
1 rain 1 m-Z; t > 10 nM time (h) above a concentration f 10 nM; Uexcz 
total drug urinary excretion over the first 24 h, given as percentage of
the administered total dose on 1 day; n.d. not done) 
Pat. Dose Cmax AUC tIA(a) 0/2(13) klo k12 k21 Vc Vss CL t > 10 nM U~xcr. 
1(1) 0.5 45.2 2.03 4.8 69 7.20 6.11 2.01 7.4 30.1 0.53 0.85 23.6 
1(4) 0.5 38.6 2.74 1.9 76 13.40 22.38 2.55 3.0 29.2 0.40 1.0 n.d. 
2(1) 0.5 24.3 2.71 7.6 133 2.76 5.15 1.72 14.6 58.1 0.41 1.2 33.9 
2(5) 0.5 27.6 2.99 1.2 149 8.02 45.95 3.29 4.6 68.3 0.37 1.0 n.d. 
Mean 33.9 2.62 3.9 107 7.85 19.90 2.39 7.40 46.4 0.43 1.0 28.8 
3(1) 0.65 22.8 2.10 8.5 167 3.00 4.40 1.11 23.1 114.0 0.69 0.75 13.8 
3(4) 0.65 23.7 2.48 11.3 203 2.08 3.39 1.00 28.2 123.5 0.59 0.90 n.d. 
4(1) 0.65 42.7 3.68 5.0 154 4.77 8.13 1.29 8.18 58.9 0.39 1.4 10.6 
4(4) 0.65 32.6 1.91 12.9 126 2.68 2.15 1.10 27.6 81.7 0.74 1.1 n.d. 
Mean 30.5 2.54 9.4 163 3.13 4.52 1.13 21.8 94.5 0.60 1.0 12.2 
5(1) 0.9 51.0 3.85 1.1 89 17.80 43.10 2.76 2.9 47.7 0.51 1.5 29.1 
5(4) 0.9 55.1 3.72 6.0 117 5.39 5.48 1.27 9.8 52.1 0.53 1.3 n.d. 
6(1) 0.9 59.8 3.17 4.0 49 7.54 8.04 3.26 8.2 28.5 0.62 1.4 38.0 
7(1) 0.9 42.7 2.96 8.6 132 4.08 3.47 1.04 19.4 84.0 0.79 1.4 23.3 
7(4) 0.9 39.7 3.09 5.0 132 5.27 7.65 1.37 4.6 30.2 0.25 1.5 n.d. 
8(1) 0.9 45.0 2.49 15.5 139 1.56 1.97 1.44 42.6 101.2 0.66 1.0 n.d. 
9(1) 0.9 156.1 8.15 8.6 99 3.06 3.89 1.87 21.0 64.8 0.64 2.9 n.d. 
Mean 64.2 3.92 7.0 108 6.39 10.5 1.85 15.5 58.4 0.57 1.8 30.1 
10(1) 1.0 43.8 2.87 I2.7 192 2.67 2.41 0.74 28.4 121.1 0.76 1.1 24.9 
10(4) 1.0 98.2 7.39 6.4 129 3.63 6.07 1.59 8.1 39.1 0.30 2.8 n.d. 
Mean 71.0 5.13 9.6 161 3.15 4.24 1.17 18.3 80.1 0.53 2.0 24.9 
11(1) 1.25 67.0 5.12 0.3 94 66.6 171.8 2.66 0.8 52.4 0.54 2.2 30.8 
11(4) 1.25 90.4 6.05 5.8 109 5.2 5.88 1.46 8.7 43.8 0.45 2.3 n.d. 
12(1) 1.25 27.2 2.74 1.0 73 11.1 53.9 6.00 8.9 89.1 0.99 1.6 24.1 
12(4) 1.25 44.2 3.81 9.3 93 2.14 3.50 2.59 33.2 78.1 0.71 2.0 n.d. 
13(1) 1.25 51.7 4.32 5.4 133 5.61 6.57 1.19 11.4 74.1 0.64 1.4 58.6 
13(5) 1.25 90.8 4.18 5.9 125 4.85 6.09 1.35 13.6 75.2 0.66 1.5 n.d. 
14(1) 1.25 43.6 4.18 6.3 109 3.80 5.98 1.83 17.2 73.4 0.66 1.8 21.0 
14(4) 1.25 52.3 4.02 4.2 111 5.12 9.9i 2.01 13.3 78.7 0.68 1.8 n.d. 
Mean 58.4 4.30 4.8 106 13.0 32.9 2.39 13.4 70.6 0.67 1.8 33.6 
15(1) 1.5 99.0 9.08 21.6 168 1.45 1.26 0.91 27.0 64.3 0.39 3.2 32.2 
15(4) 1.5 92.6 8.39 40.7 286 0.81 0.62 0.51 42.6 95.0 0.35 3.0 n.d. 
16(1) 1.5 100.1 9.45 15.5 228 1.74 2.26 0.77 27.6 108.0 0.48 2.7 20.2 
16(4) 1.5 53.3 6.81 8.5 177 2.51 4.77 1.27 20.4 97.0 0.51 2.4 n.d. 
17(1) 1.5 53.0 6.40 2.9 126 7.66 15.4 1.74 6.9 68.1 0.53 2.8 7.0 
17(4) 1.5 81.9 6.31 0.3 133 0.75 179.5 1.78 0.8 83.0 0.61 2.5 n.d. 
18(1) 1.5 83.4 5.47 15.5 124 1.39 1.83 1.80 57.7 116.0 0.80 2.2 22.3 
18(4) 1.5 34.9 4.15 5.1 77 4.15 7.37 2.94 18.4 64.7 0.76 Z3 n.d. 
19(1) 1.5 62.2 4.34 6.3 156 3.71 6.49 1.33 9.5 79.2 0.35 2.7 n.d. 
Mean 73.4 6.71 12.9 164 2.69 24.4 1.45 23.4 86.1 0.53 2.6 20.4 
infusion the concentration exceeded the topotecan concen- 
tration and declined in parallel with topotecan (Fig. 2). The 
pharmacokinetic profiles of the lactone ring-opened form of 
topotecan could be modelled by Eq. (3), which described 
both the rates of formation and the elimination of the 
metabolite in a one-compartment model. The model in- 
volved constant rate drug formation and elimination both 
restricted to one compartment. The pharmacokinetic char- 
acteristics of the metabolite are summarized in Table 2. 
Maximal plasma concentrations were reached at t = 47.6 
(range 21-102)  min, i.e. about 20 min after the end of the 
infusion. The mean half-life tl/2(2), calculated from the 
terminal inear phase of the metabolite curve, was 123.2 
(range 32-265)  min and tl/2(1), the mean half-life of the 
initial phase of the curve, was 29.0 (range 5.6-99.5) min. 
The apparent distribution volume of the metabolite was 15.3 
(range 1.9-64.5) 1/m 2 and the mean total clearance was 0.4 
(range 0.17-1.57) 1min-1 m-2. Linear regression analysis of 
Cmax and AUC of the metabolite versus the dose (mg m-2 
day -t) of topotecan shows relationships with r = 0.66 and 
r = 0.75, respectively. Linear regression analysis of the total 
AUC (lactone + hydroxy acid) versus the dose (mg m -2 
day -1) of topotecan shows a linear relationship with 
r = 0.78. The other parameters how no dose-related 
trends. There is, however, a linear relationship between 
the AUC of topotecan and the AUC of its lactone ring- 
opened form (r = 0.69). 
Figure 3 shows the mean ratio between the concentration 
of the parent and ring-opened metabolite (lactone/hydroxy 
acid) as a function of time with its 95% confidence interval. 
Table 2 Pharmacokinetics of 
topotecan's metabolite. (Pat. 
patient number with the day of 
course in round brackets; Dose 
mg m -2 day-l; Cm= (nM) reached 
at time Tma.~ (min); AUC p,M 9 
rain; F/2(1), ti/2(2) min; fm frac- 
tion of topotecan converted into 
the metabolite; VMf,~ Lima; CL/fm 
1 min-1 m-2) 
Pat. Dose Cmax rrnax AUC tV2(1) d/2(2) Vm/fm CL/fm 
1(1) 0.5 19.8 21 1.26 10.7 37 13.4 0.87 
1(4) 0.5 8.0 31 2.52 10.2 113 6.3 0.43 
2(1) 0.5 9.42 31 0.69 28.5 32 64.5 1.57 
2(5) 0.5 11.5 45 2.25 5.6 186 3.9 0.48 
Mean 12.2 32 1.68 13.8 92 22.0 0.84 
3(1) 0.65 10.1 102 3,10 33.0 126 22.0 0.47 
3(4) 0.65 9.7 45 2.44 27.8 107 23.7 0.59 
4(1) 0.65 18.2 89 7.07 61.1 94 17.6 0.20 
4(4) 0.65 17.0 93 2.82 50.4 55 36.3 0.50 
Mean 13.8 82 3.86 43.1 96 24.9 0.44 
5(1) 0.9 20.2 46 4.74 12.7 134 7.5 0.41 
5(4) 0.9 20.0 31 3.85 12.2 125 9.0 0.51 
6(1) 0.9 21.5 60 6.18 27.1 130 12.5 0.32 
7(1) 0.9 45.6 30 7.93 20.7 63 21.3 0.71 
7(4) 0.9 24.5 60 6.98 7.8 144 1.9 0.17 
8(1) 0.9 26.6 30 2.79 34.2 108 12.3 0.25 
9(1) 0.9 69.7 30 11.54 22.4 141 9.4 0.29 
Mean 32.6 41 6.29 19.5 121 10.6 0.38 
10(1) 1.0 14.3 45 3.31 32.9 98 31.3 0.66 
10(4) 1.0 34.5 45 7.45 19.0 118 7.9 0.29 
Mean 24.4 45 5.38 26.0 108 19.6 0.48 
11(1) 1.25 39.0 90 16.2 8.5 265 2.1 0.17 
11(4) 1.25 41.8 30 13.6 19.7 180 5.7 0.20 
12(1) 1.25 29.7 60 6.07 8.9 137 5.8 0.45 
12(4) 1.25 27.1 30 5.42 32.0 81 23.0 0.50 
13(1) 1.25 22.6 35 4.13 16.7 100 16.2 0.67 
13(5) 1.25 24.8 30 4.60 23.3 111 20.1 0.60 
14(1) 1.25 18.2 36 4.24 22.6 109 20.8 0.64 
14(4) 1.25 17.3 31 4.69 18.6 131 15.6 0.58 
Mean 27.6 43 7.37 18.8 139 13.7 0.48 
15(1) 1.5 48.4 30 11.3 64.8 76 16.8 0.36 
15(4) 1.5 38.7 42 9.16 99.5 118 18.7 0.26 
16(1) 1.5 47.8 35 12.8 41.9 161 15.7 0.26 
16(4) 1.5 37.9 50 12.7 64.7 90 30.8 0.33 
17(1) 1.5 35.2 32 9.98 15.3 203 4.2 0.19 
17(4) 1.5 47.6 45 17.1 9.2 179 3.0 0.23 
18(1) 1.5 56.7 30 14.4 85.0 96 13.3 0.25 
18(4) 1.5 49.9 90 13.3 28.0 184 4.2 0.24 
19(1) 1.5 42.0 90 13.4 9.8 156 4.0 0.28 
Mean 44.9 49 12.7 46.4 140 12.3 0.27 
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Fig. 3 Mean ratio between plasma concentrations of topotecan and its 
ring-opened metabolite (lactone/hydroxy acid) as function of time, 
with its 95% confidence interval 
The ratio declines rapidly from approximately 7 to 1, 
followed by a slow decrease to about 0.17 at 6 h after the 
start of infusion. 
The pharmacokinetic parameters calculated from the 
analysis on day 1 for each patient are comparable with the 
values obtained on day 4 or 5 for the same patient (paired 
Student's t-test; P < 0.94). However, in two patients (4 and 
i0; Tables 1, 2) large differences in AUC values were 
observed. 
Hematological toxicity 
In all 48 patients the main toxicity was myelosuppression, 
especially granulocytopenia, with 56% of the evaluable 
courses resulting in grade 4 granulocytopenia. Thrombocy- 
topenia was much less frequent and less severe (mean nadir 
125 _+ 87 x 109/1). Anemia occurred regularly but was only 
incidentally severe (average decrease of 16% +_6%). The 
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Table 3 Precision of models correlating (log-) %decr in ANC versus 
the dose and pharmacokinetic parameters. The precision is evaluated 
by using the percentage root mean square rror (%RMSE) value and its 
standard error (SE). The smaller the %RMSE, the better the relation is 
described by the model (P the pharmacokinetic parameter of interest; 
r correlation coefficient) 
Model: Linear Loglinear Emax sigmEmax 
%decrANC = a 9 P + b log(%decr) = (ME)(P) (ME)(P) r~ 
a 9 P + b (Ps0) + (P) (Ps0)H + (p)H 
P r r 
Dose 11.2 (2.1) .90 11.4 (2.2) .89 21.5 (3.7) 13.8 (2.6) 
Cmax 20.0 (3.5) .61 20.1 (3.5) .61 27.1 (4.6) 18.8 (3.4) 
Time above 1.0 nM 25.5 (4.4) .04 25.3 (4.3) .07 30.1 (4.6) 38.6 (6.7) 
Time above 10 nM 13.5 (2.5) .84 14.5 (2.7) .82 22.7 (3.8) 13.0 (2.5) 
AUC of lactone 20.1 (3.5) .61 20.4 (3.5) .59 25.5 (4.2) 17.5 (3.2) 
AUC of hydroxy acid 15.6 (2.9) .81 16.1 (2.9) .77 28.5 (6.2) 18.8 (3.6) 
Total AUC 15.1 (2.8) .81 15.8 (2.9) .78 21.5 (3.7) 13.6 (2.6) 
nadirs of both leukocytopenia and granulocytopenia were 
between day 8 and 15 and were of brief duration (3 -5  days). 
Previous chemo- and/or adiotherapy could not be identified 
as risk factors. There were no indications of cumulative 
myelotoxicity. In contrast, the extent of myelosuppression 
during the first course of treatment appeared to be repetitive 
in all subsequent courses. 
Non-hematological toxicity 
Nausea and vomiting were found to be non-dose-dependent 
and occurred in 49 courses (23%), being classed as grade 2 
or 3 in 29 courses (13%). They were easily prevented with 
standard antiemetics in most patients in subsequent courses. 
Alopecia was also not dose-dependent and occurred in 9 
patients (19%), being total in 5 (10%). Other incidental side 
effects were asymptomatic hypotension (35 courses, 16%), 
mild proteinuria (8 courses, 4%), and microscopic hematuria 
(6 courses, 3%). There was no gastrointestinal, cardiac, 
liver, renal, or skin toxicity. 
versus other pharmacokinetic parameters did not yield any 
significant relationship. 
We compared four different models for their ability to 
describe the data. All data were modelled using a linear, a 
log-linear, an Emax and a sigmoidal Emax model [Eqs. (5), (6), 
(7), (8), respectively]. In general, the decrease (%) in ANC, 
which was dose-limiting, showed better correlations than 
that in WBC (data not shown). All models predicting the 
decrease (%) in WBC were more or less equally predictive: 
all RMSE% values were greater than 19.3% (median 21.6%, 
ranging to 54.8%), and all correlation coefficients were 
smaller than 0.68. The decrease (%) in ANC appeared to 
be best related to the dose (mg m -2 day-0, the total AUC, 
and the time period above > 10 nM (Table 3, Figs. 4-6) .  All 
models and comparable precision. Using the sigmEmax 
model, the estimate for the dosage associated with 50% 
decrease in ANC is 0.6 mg m2 day-1. A dosage of 1.5 mg 
m -2 day -1 for 5 consecutive days was considered the 
maximum tolerable dose (MTD) and recommended for 
phase II studies [30]. 
Responses 
too 
Response could be evaluated in 40 patients. A partial 
remission was seen in 3 female patients (1 with small-cell ~ 75 
lung cancer, 1 with non-small-cell ung cancer, and 1 with u 
metastatic pancreatic ancer with a partial remission of the 
liver metastases). Unfortunately, these patients did not ~ 50 
participate in our pharmacokinetic studies. Stable disease ~- 
was seen in 24 patients. =g 
~8 2s 
Modelling pharmacokinetic-pharmacodynamic relationships 
The pharmacokinetic parameters obtained from 19 patients 
(i. e. the Cmax, the time period above a concentration of 
1.0 nM or 10 nM and the AUC of topotecan, the AUC of its 
metabolite, the total AUC, and the dose), were plotted 
against the percentage decrease in WBC and in ANC. 
Plots of the percentage decrease in ANC and in WBC 
[]111 III f 
./... 
o i 2 5 
Time above 10 nM (h) 
Fig. 4 Relation between the time above a concentration f 10 nM of 
topotecan and the decrease (%) in ANC. The solid line represents he 
fit of the data to a sigEmax model 
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Fig. 5 Relation between the total AUC (lactone + hydroxy) and the 
%decr in ANC. The solid line represents he fit of the data ot a sigEma~ 
model 
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Fig. 6 Relation between the dose (mg/m2/day) and the %decr in ANC. 
The solid line represents he fit of the data to a sigEmax model 
Discuss ion  
The chemical conversion of topotecan i to the ring-opened 
species appeared from the start of infusion and continued 
until the last measured concentration (Fig. 3). The highly 
sensitive HPLC assay (detection limit -~ 0.4 nM) allowed 
selective measurement of topotecan and its ring-opened 
form [2]. Therefore, it was possible to construct a complete 
pharmacokinetic curve even at the first dose step of the 
study. In plasma at 37 ~ C, no significant amount of the 
reverse reaction of the ring-opened form into topotecan 
occurs [2] and, therefore, the reversibility of the reaction 
has not been taken into account in the pharmacokinetic 
modelling. The experimental data fitted well to the models 
used (Eqs. 1-3), indicating that this is justified. Unlike 
camptothecin, topotecan does not produce hemorrhagic 
cystitis, despite a 26% drug excretion in the urine over the 
first 24 h, and it has a reproducible and reduced toxicity 
profile. Compared with the 17% of camptothecin that was 
found in the urine after 48 h [8], the occurrence of 
hemorrhagic ystitis is most likely to be related to the 
improved water solubility and not the extent of urinary 
excretion. 
The median ratio k21/M2, reflecting the return and entry 
of topotecan from the peripheral compartment, is 0.32, 
indicating the tendency of the drug to stay behind in this 
compartment. Extensive binding to tissues and other com- 
ponents of this compartment may occur, which retards the 
return into the central compartment. Although this conclu- 
sion is speculative, the high value for Vss is in agreement 
with extensive tissue binding in a peripheral compartment. 
Tissue binding may be more important than protein binding 
in this compartment, as the binding to human plasma 
proteins is only 21% [14]. The slow return into the central 
compartment may explain the relatively long period of time 
for which topotecan is detectable in plasma. The volume of 
distribution of the central compartment approximates that of 
total body water. This compartment provides the (physio- 
logical) pH, in which the hydrolysis reaction is continuously 
favored. This mechanism ay determine mainly the elimi- 
nation of the parent drug (M0 ~ Xf), although renal or 
hepatic elimination can not be excluded. 
The plasma concentration versus time plots of the 
topotecan metabolite could be described adequately using 
a one-compartment model (Eq. 3). After about 1.5 h the 
concentrations of the parent drug and metabolite decline in 
parallel, with identical slopes. Furthermore, since the time 
course of the metabolite is determined by the slowest step in 
the sequence of formation and elimination, which is the rate 
of formation (~ > ~f), these data indicate that the 
metabolite has a shorter elimination half-life than the 
parent drug. Moreover, the ring-opened metabolite with a 
free and dissociated carboxylic function at physiological pH 
can be considered to be more highly polar and, hence, more 
readily and quickly eliminated from the body than the parent 
drug. The concentration f the metabolite in plasma might 
therefore be expected always to be lower than that of the 
parent drug. This, however, is not the case: the ratio between 
the plasma concentration of the parent and metabolite 
(Fig. 3) falls below 1 by 1 h after the start of infusion. A 
possible explanation might be the smaller volume of 
distribution of the metabolite, which is limited to the body 
water. Thus, the plasma concentrations do not reflect the 
total body amount of both forms. In fact, the central 
compartment contains about 17% of the total amount of 
topotecan present in the body, given by the ratio X~kl0. The 
half-life for metabolite limination, calculated from Xe, is 
29.0 (range 5.6-99.5) min, the half-life for metabolite 
formation, calculated from )~f, is 123.2 (range 32-265) min. 
The pharmacodynamic-pharmacokinetic plots ould be 
described adequately by sigmoidal Emax models. Linear 
models were, generally, equally predictive, suggesting the 
modelling of the values of the pharmacokinetic parameters 
occurred in the linear part of the sigmoidal models. How- 
ever, although similar results were obtained, on biological 
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grounds a sigmoidal model is more obvious and, therefore, 
preferable. The MTD (1.5 mg m -2 day-0 administered in
phase II studies would result in an average percentage 
decrease in ANC of 87%, as predicted by the sigmEmax 
model. The estimate for Ps0 (the dose associated with 50% 
decrease in ANC) is 0.6 mg m -2 day -1. This is in accordance 
with the findings of others [9, 22] (i.e. 0.8 mg m -2 day-l). 
These published pharmacodynamic studies also suggested 
that the relationship between the dose (mg m -2 day -1) and 
total AUC and decrease (%) in ANC were the only ones [9, 
22]. Other relationships with pharmacokinetic parameters 
could not be detected. This is in contrast to the present study, 
where plots of percentage decrease in ANC versus the dose, 
the AUC of topotecan, the AUC of its metabolite, and the 
total AUC were quite similar. The differences found in our 
study as against other reports may be explained in part by 
the sensitive and selective measurement of both forms. In 
other studies the HPLC method used was selective for only 
the lactone (closed) form of topotecan, whereas the ring- 
opened form was calculated as the total topotecan concen- 
tration (after sample acidification) minus the concentration 
of the lactone form [5, 9, 26, 33]. 
In conclusion, it is important hat the pharmacokinetics 
of topotecan and its inactive metabolite are described, since 
this may help us to determine the optimal mode of drug 
administration and the optimal dosage, and extend our 
understanding of the differences found in pharmacody- 
namic outcome. Further research into the pharmacokinet- 
ic-pharmacodynamic relationships of topotecan is needed. 
For example, day-to-day variation within patients hould be 
investigated, since the pharmacokinetics can vary very 
widely between days 1 and 4, as noted in two of our 
patients. With the aid of a l imited-sampling model we 
have recently developed [29], which requires only one 
plasma concentration determination, we are now perform- 
ing a pharmacokinetic study in which we determine AUC 
values on 5 consecutive days. With this information, the 
pharmacokinetic-dynamic relationships will be further ex- 
plored. The encouraging results of phase I and II studies [17, 
20, 24] legitimate this goal. 
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